CompletedPhase 3NCT03697109

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Studying Adrenal Cushing syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Corcept Therapeutics
Principal Investigator
Andreas Moraitis, MD, M.D
Corcept Therapeutics
Intervention
Relacorilant(drug)
Enrollment
152 enrolled
Eligibility
18-80 years · All sexes
Timeline
20182024

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03697109 on ClinicalTrials.gov

Other trials for Adrenal Cushing syndrome

Additional recruiting or active studies for the same condition.

See all trials for Adrenal Cushing syndrome

← Back to all trials